Loading…
Based on limited metadata available, Lernapharm (Loris) Inc. received an FDA Warning Letter on September 4, 2018, regarding an unspecified product category classified as "Other." Without access to the full letter text or detailed subject information, the specific nature of the regulatory violations cannot be determined from the metadata alone. The issuing office is also not identified in the available information, limiting clarity on the regulatory pathway or specific FDA division involved.